This is a Phase 1 single center, open, dose-escalation clinical trial. According to the Chinese guidelines for vaccine clinical trial, the sample size of a phase 1 clinical trial should be at least 20. In this study, a total of 60 participants will be included.
30 participants will be firstly recruited and assigned to receive the low dose Ad5-EBOV.
After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose Ad5-EBOV.
The whole follow-up period for each participant will be 28 days.